This episode of the Business of Biotech is fire. In fact, it’s an interview with SalioGen Therapeutics Chairman and CEO Ray Tabibiazar, M.D.,, whose last name _literally translates_ to “Dr. Fire.” Learn how he got that name, what’s shaped his technology-agnostic philosophy on therapeutic development, the advantages of a genome engineering technology that leverages proprietary mammal-derived enzymes, rather than viruses, and how SalioGen is possibly carrying forth a pipeline that’s 15 candidates deep and addressing eye, liver, heart, lung, bone marrow, and kidney diseases.